Study Overview
This study looked at using a combination of sintilimab (an anti-PD-1 antibody) and chemotherapy as a treatment before surgery for patients with resectable esophageal squamous cell carcinoma (ESCC). The goal was to see how effective and safe this treatment is.
Study Details
In this phase II study, patients diagnosed with resectable ESCC were treated with sintilimab and chemotherapy (nab-paclitaxel and cisplatin) every three weeks for two cycles. The main goal was to measure the rate of complete response in the tissue after treatment.
Results
From November 2020 to November 2022, 29 patients participated, and 27 completed the treatment. Out of these, 21 patients had surgery. The results showed:
- 28.6% of patients had a complete response (6 out of 21).
- 42.9% had a major response (9 out of 21).
The most common serious side effects were low white blood cell counts (26.7%) and low neutrophil counts (20%). Importantly, there were no delays or unexpected complications during surgery due to the treatment.
Conclusions
The combination of sintilimab and chemotherapy was well-tolerated and showed promising results for patients with ESCC. This treatment could be a good option for patients, especially in China.
Next Steps for Clinics and Patients
Based on the trial data, clinics can:
- Set clear goals for treatment outcomes.
- Identify measurable results to track progress.
- Consider using AI tools to enhance treatment management.
Start with small pilot projects to test these approaches and monitor their effectiveness.
Contact Us for AI Solutions
If you’re interested in AI solutions for medical management, reach out to us:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
